A61K 2039/5158
Antigen-pulsed cells
Official title: {Antigen-pulsed cells, e.g. T-cells}
A61K2039/5158 (Antigen-pulsed cells) appears on 693 US grants and 1,072 published applications in this corpus.
Search patents in A61K- Granted patents
- 693
- Published applications
- 1,072
- Assignees
- 395
- Inventors
- 1,352
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 2 | 0 |
| 1995 | 2 | 0 |
| 1996 | 1 | 0 |
| 1997 | 2 | 0 |
| 1998 | 8 | 0 |
| 1999 | 3 | 0 |
| 2000 | 6 | 0 |
| 2001 | 10 | 3 |
| 2002 | 3 | 15 |
| 2003 | 2 | 20 |
| 2004 | 4 | 16 |
| 2005 | 7 | 19 |
| 2006 | 6 | 15 |
| 2007 | 4 | 25 |
| 2008 | 3 | 11 |
| 2009 | 12 | 16 |
| 2010 | 13 | 14 |
| 2011 | 14 | 22 |
| 2012 | 8 | 15 |
| 2013 | 9 | 19 |
| 2014 | 10 | 18 |
| 2015 | 14 | 23 |
| 2016 | 13 | 23 |
| 2017 | 15 | 67 |
| 2018 | 34 | 77 |
| 2019 | 67 | 86 |
| 2020 | 65 | 88 |
| 2021 | 77 | 111 |
| 2022 | 67 | 144 |
| 2023 | 54 | 81 |
| 2024 | 99 | 69 |
| 2025 | 31 | 53 |
| 2026 | 25 | 22 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Suppression of diabetes using exosomes from stem cell programmed myeloid cells22 Sep 2026US 12,741,015 B2Creative Medical Technologies, Inc.
- Peptide tags for ligand induced degradation of fusion proteins15 Sep 2026US 12,735,463 B2Dana-Farber Cancer Institute, Inc.
- Methods of preparing anti-human papillomavirus antigen T cells11 Aug 2026US 12,702,706 B2The United States of America, as represented by the Secretary, Department of Health and Human Seervices
- T cell recruiting polypeptides capable of binding CD123 and TCR α/β4 Aug 2026US 12,698,329 B2Ablynx N. V.
- CTL peptide epitopes and antigen-specific T cells, methods for their discovery, and uses thereof16 Jun 2026US 12,656,344 B2Oslo Universitetssykehus Hf
- Cd4+ cytotoxic t cells and methods of use thereof8 Oct 2026US 2026/0308522 A1Dana-Farber Cancer Institute, Inc.
- Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy1 Oct 2026US 2026/0293881 A1Iovance Biotherapeutics, Inc.
- Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy17 Sep 2026US 2026/0272985 A1Iovance Biotherapeutics, Inc.
- Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy17 Sep 2026US 2026/0272986 A1Iovance Biotherapeutics, Inc.
- Ionizable lipids for nucleic acid delivery17 Sep 2026US 2026/0273066 A1Global Life Sciences Solutions Canada ULC
Most cited
By later US patents
- Methods for selectively stimulating proliferation of T cells341US 5,858,358 ADana-Farber Cancer Institute, Inc. · 1999
- CD9 antigen peptides and antibodies thereto326US 5,883,223 A1999
- Immunotherapy against several tumors, such as lung cancer, including NSCLC198US 10,071,148 B2Immatics Biotechnologies GmbH · 2018
- Mesenchymal stem cells for prevention and treatment of immune responses in transplantation181US 6,328,960 B1Osiris Therapeutics, Inc. · 2001
- Methods of cell culture for adoptive cell therapy156US 8,956,860 B22015